Abrégé

The present invention provides a method for treating canine B cell lymphoma that has a superior effect as compared to existing methods.　Provided is a method for treating canine B cell lymphoma wherein a monoclonal antibody for canine CD20 and a chemotherapeutic agent are administered in combination, either simultaneously or sequentially. The chemotherapeutic agent is one or more agents from among vincristine, cyclophosphamide, prednisolone, and doxorubicin, and is administered in combination with the monoclonal antibody for canine CD20, either simultaneously or sequentially.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 31/475 - QuinoléinesIsoquinoléines ayant un cycle indole, p. ex. yohimbine, réserpine, strychnine, vinblastine
• A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
• A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
• A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• A61P 35/00 - Agents anticancéreux
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
• C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs

Abrégé

Provided is a method for assisting in determining a treatment plan for a dog that has a skin condition like atopic dermatitis.　Provided is a method that includes the following steps: a) a step for measuring the TARC level included in a blood sample taken from a subject, and b) a step for determining that treatment for atopic dermatitis is useful when the TARC level is equal to or greater than a threshold value, and determining that treatment for another disease is useful when the TARC level is less than the threshold value.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

A low-variation and highly reproducible method for measuring antibody-dependent cellular cytotoxicity activity of an antibody for a dog as the subject of administration is provided. A low-variation and highly reproducible method for measuring antibody-dependent cellular cytotoxicity activity of an antibody for a dog as the subject of administration is provided. A method for measuring antibody-dependent cellular cytotoxicity activity comprising a step of causing an antibody and cells in which a canine CD16-canine Fcε receptor γ chain fusion protein is expressed in human-derived NK cells to act on canine tumor-derived cells or cells which express a canine tumor antigen and a step of detecting the cell death of the canine tumor-derived cells or the cells which express the canine tumor antigen. Also, the method for measuring antibody-dependent cellular cytotoxicity activity in which the human-derived NK cells are NK-92 cells.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C07K 14/735 - Récepteurs Fc
• G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées

Produits et services

Pharmaceutical preparations; pharmaceutical preparations for animals; fungicides; teeth filling material; dental abrasives; dietary supplements; dietetic food adapted for medical purposes; dietary supplements for animals; semen for artificial insemination; enzymes for veterinary purposes.

Abrégé

To provide a monoclonal antibody against canine CD20 having a more excellent effect than existing antibodies. To provide a monoclonal antibody against canine CD20 having a more excellent effect than existing antibodies. The present invention provides a monoclonal antibody or antibody fragment against canine CD20 that has a heavy chain variable region consisting of an amino acid sequence of SEQ ID NO: 1 or an amino acid sequence in which one or several amino acids are deleted, substituted, or added in the amino acid sequence of SEQ ID NO: 1, and a light chain variable region consisting of an amino acid sequence of SEQ ID NO: 2 or an amino acid sequence in which one or several amino acids are deleted, substituted, or added in the amino acid sequence of SEQ ID NO: 2, and that has a light chain constant region consisting of an amino acid sequence of SEQ ID NO: 3 or an amino acid sequence in which one or several amino acids are deleted, substituted, or added in the amino acid sequence of SEQ ID NO: 3.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61P 35/00 - Agents anticancéreux

Abrégé

Provided are a treatment method and a therapeutic agent for canine tumor. A pharmaceutical composition for treating canine tumor, comprising, as an active ingredient, a compound that inhibits the binding of canine CCL17 and canine CCR4. A method for predicting the efficacy of a compound that inhibits the binding of canine CCL17 and canine CCR4 on the treatment of canine tumor is also provided.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention addresses the problem of providing a monoclonal antibody against canine CD20, the antibody being superior in effect to conventional antibodies.　Provided is a monoclonal antibody or an antibody fragment against canine CD20, the monoclonal antibody comprising: a heavy chain variable region that comprises the amino acid sequence represented by SEQ ID NO:1 or an amino acid sequence with deletion, substitution or addition of one to several amino acids in the amino acid sequence represented by SEQ ID NO:1; a light chain variable region that comprises the amino acid sequence represented by SEQ ID NO:2 or an amino acid sequence with deletion, substitution or addition of one to several amino acids in the amino acid sequence represented by SEQ ID NO:2; and a light chain constant region that comprises the amino acid sequence represented by SEQ ID NO:3 or an amino acid sequence with deletion, substitution or addition of one to several amino acids in the amino acid sequence represented by SEQ ID NO:3.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 35/00 - Agents anticancéreux
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C12N 15/13 - Immunoglobulines
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

The present invention addresses the problem of providing a means for improving the diffusibility and dispersibility of an active ingredient in udders, in the case of preparing a formulation of granulocyte-macrophage colony stimulating factor which serves as an alternative to an antibiotic and is usable as a novel therapeutic agent for cow mastitis.　The present invention pertains to an injection for mastitis, said injection containing granulocyte-macrophage colony stimulating factor as an active ingredient together with a medium-chain fatty acid monoglyceride as an additive.

Classes IPC  ?

• A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p. ex. inducteurs d'ovulation ou de spermatogénèse
• A61P 15/14 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour les troubles de la lactation, p. ex. galactorrhée
• C07K 14/535 - CSF du type granulocyteCSF du type granulocyte-macrophage
• A61K 9/08 - Solutions
• A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
• A61K 38/19 - CytokinesLymphokinesInterférons

Produits et services

Pharmaceutical preparations; veterinary preparations; dietary supplements for humans; dietetic beverages adapted for medical purposes; dietetic food adapted for medical purposes; dietary supplements for animals; semen for artificial insemination; preserving agents of semen for artificial insemination for medical and veterinary use; cells for medical purposes; preserving agents of cells for medical purposes; biological tissue cultures for medical purposes; preserving agents of biological tissue cultures for medical purposes; dietary supplements for animals for non-medical purposes. Protein-enriched feed for animal consumption; animal foodstuffs; inedible animals; inedible fishes; live birds; live insects; live edible fishes; live edible shellfishes; live silkworm eggs; eggs for hatching.

Produits et services

Pharmaceutical preparations; pharmaceutical preparations for animals; fungicides; teeth filling material; dental abrasives; dietary supplements; dietetic food adapted for medical purposes; dietary supplements for animals; semen for artificial insemination; enzymes for veterinary purposes.

Produits et services

Veterinary pharmaceutical preparations for the treatment of allergy diseases, renal diseases, cancer and infections; dietetic beverages adapted for medical purposes for animals; dietetic food adapted for medical purposes for animals; dietary supplements for animals; semen for artificial insemination; antimicrobial preserving agents of semen for artificial insemination for medical and veterinary use; stem cells for medical purposes; antimicrobial agents of cells for medical purpose; biological tissue cultures for medical purposes; antimicrobial agents of biological tissue cultures for medical purposes; dietary supplements for animals for non- medical purposes Protein-enriched feed for animal consumption; animal foodstuffs; live inedible animals; live inedible fishes; live birds; live insects; live edible fishes; live edible shellfishes; live silkworm eggs; eggs for hatching

Produits et services

Pharmaceutical preparations, namely, pharmaceutical preparations for treatment of renal anemia; pharmaceutical preparations for animals, namely, pharmaceutical preparations for animals for treatment of renal anemia; fungicides; teeth filling material; dental abrasives; dietary supplements; dietetic food adapted for medical purposes; dietary supplements for animals; semen for artificial insemination; enzymes for veterinary purposes

Abrégé

The present invention comprises: a hollow needle 7; a fixed part 8 fixed to the outer periphery of the proximal end section of the needle 7; a connection tube 10 that is attached to a flexible protruding section 9 protruding toward a side of the fixed part 8 opposite to the needle, that interconnects with the needle 7, and that is configured such that the distal end section 1a of a syringe 1 can be fitted into the connection tube from the side opposite to the needle; and a gripping part 11 projecting outward from the outer peripheral surface of the fixed part 8. The connection tube 10 is configured such that a hematocrit tube 13 can also be fitted thereinto from the side opposite to the needle.

Classes IPC  ?

• A61D 7/00 - Dispositifs ou méthodes pour l'introduction de remèdes, solides, liquides ou gazeux ou d'autres produits dans ou sur le corps des animaux
• A61M 5/32 - AiguillesParties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchonAccessoires pour introduire l'aiguille dans le corps ou l'y maintenirDispositifs pour la protection des aiguilles

Abrégé

Provided are a treatment method and a therapeutic agent for canine tumors. A pharmaceutical composition for treating canine tumors that includes as an active ingredient a compound that inhibits the binding of canine CCL17 and canine CCR4.

Classes IPC  ?

• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 35/00 - Agents anticancéreux
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

Provided are an anti-canine TARC antibody for use in the treatment and diagnosis of canine atopic dermatitis, and a method for treating or diagnosing canine atopic dermatitis using the same. An anti-canine TARC monoclonal antibody binding to canine TARC, comprising a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 2 and a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 4, or a functional fragment thereof binding to canine TARC.

Classes IPC  ?

• C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
• G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• C12N 15/09 - Technologie d'ADN recombinant
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales

Abrégé

Provided is a method for diagnosing lymphoma in a dog. A method for diagnosing lymphoma in a dog, comprising: measuring CD70 expressed in lymphocytes in peripheral blood collected from the dog using an anti-dog CD70 monoclonal antibody which can bind to canine CD70 or a functional fragment of the monoclonal antibody which can bind to canine CD70; and determining that the dog is suffering from lymphoma when CD70 is expressed in the lymphocytes.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C12N 1/15 - ChampignonsLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 1/19 - LevuresLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C12N 15/09 - Technologie d'ADN recombinant
• C12P 21/08 - Anticorps monoclonaux
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

The object of the present invention is to provide an anti-canine PD-1 antibody or an anti-canine PD-L1 antibody, an agent for inhibiting binding between a canine PD-1 and a canine PD-L1 containing such an antibody, a method for inhibiting binding between a canine PD-1 and a canine PD-L1 comprising using such an antibody, and a gene encoding such an antibody. An anti-canine PD-1 antibody that specifically binds to a canine PD-1 consisting of the amino acid sequence set forth in SEQ ID NO: 1 and an anti-canine PD-L1 antibody that specifically binds to a canine PD-L1 consisting of the amino acid sequence set forth in SEQ ID NO: 6 are produced. An agent for inhibiting binding between a canine PD-1 and a canine PD-L1 containing such an antibody is also produced.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• C12N 15/09 - Technologie d'ADN recombinant

Abrégé

The present invention provides a synthetic peptide capable of inducing an antibody to an autoantigen, and specifically, provides: a multiplexed same type-antigenic peptide having a dendritic core and B-cell recognition peptides, wherein the multiplexed same type-antigenic peptide comprises 4 to 8 B-cell recognition peptides of the same type that are bound to the terminal ends of the dendritic core directly or via a spacer, and each B-cell recognition peptide is bound to the terminal end of the dendritic core directly or via a spacer; an antibody production-inducing agent having the peptides; and a method for producing the peptide.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• C07K 16/42 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des immunoglobulines (anticorps anti-idiotypiques)
• C07K 17/02 - Peptides immobilisés sur, ou dans, un support organique
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains

Abrégé

Provided is an anti-canine TARC antibody used for treatment and diagnosis of canine atopic dermatitis and a method for treatment or diagnosis of canine atopic dermatitis using the same. An anti-canine TARC monoclonal antibody binding to canine TARC or the functional fragment thereof binding to canine TARC includes a heavy chain variable region comprising an amino acid sequence represented by SEQ ID NO: 2 and a light chain variable region comprising an amino acid sequence represented by SEQ ID NO: 4.

Classes IPC  ?

• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• C12N 1/15 - ChampignonsLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 1/19 - LevuresLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C12N 15/09 - Technologie d'ADN recombinant
• C12P 21/08 - Anticorps monoclonaux
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

Problem to be Solved: The present invention is intended to provide a polynucleotide encoding the light-chain variable region and the heavy-chain variable region of an anti-dog IgE antibody; and an anti-dog IgE antibody containing these variable regions. Solution: The present invention is DNA encoding a heavy-chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 2 or 6 and DNA encoding a light-chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 4 or 8, and an anti-dog IgE monoclonal antibody which binds to dog IgE, containing these variable regions or a functional fragment thereof which binds to dog IgE.

Classes IPC  ?

• C07K 16/42 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des immunoglobulines (anticorps anti-idiotypiques)
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

This invention provides a method of preparing a β-hematin crystal comprising a step of heating, the β-hematin crystal obtained by such method, and a vaccine adjuvant composition containing the β-hematin crystal. The β-hematin crystal has a needle-like morphology, it has an average particle size of 0.6 to 1.2 μm, and it exhibits main peaks characteristics for angles of diffraction (2θ) of 7.4°, 12.2°, 21.6°, and 24.1° in an X-ray diffraction pattern obtained by powder X-ray diffractometry with Cu—Kα rays (with each peak including a plus-minus 0.2° diffraction angle).

Classes IPC  ?

• C07D 487/22 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes dans le système condensé, non prévus par les groupes dans lesquels le système condensé contient au moins quatre hétérocycles
• C07F 15/02 - Composés du fer
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques

Abrégé

The present invention addresses the problem of providing: an anti-canine PD-1 antibody or an anti-canine PD-L1 antibody; an agent for inhibiting binding of canine PD-1 and canine PD-L1 that contains said antibody; a method for inhibiting binding of canine PD-1 and canine PD-L1 that uses said antibody; and a gene that codes said antibody. An anti-canine PD-1 antibody that binds specifically to canine PD-1 comprising an amino acid sequence represented by SEQ ID NO: 1 or an anti-canine PD-L1 antibody that binds specifically to canine PD-L1 comprising an amino acid sequence represented by SEQ ID NO: 6 are produced. Furthermore, an agent for inhibiting binding of canine PD-1 and canine PD-L1 that contains said antibody is produced.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 35/00 - Agents anticancéreux
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• C12N 15/09 - Technologie d'ADN recombinant

Abrégé

　The present invention provides a synthetic peptide whereby antibodies to an autoantigen can be derived, and specifically provides: a multiplex alloantigenic peptide including a dendritic core and a B-cell-recognition peptide, the multiplex alloantigenic peptide including four to eight B-cell recognition peptides of the same type bonded directly or via a spacer to a terminal end of the dendritic core, the peptides being bonded directly or via a spacer to the terminal end of the dendritic core; an antibody production inducing agent including the peptide; and a method for producing the peptide.

Classes IPC  ?

• C07K 17/02 - Peptides immobilisés sur, ou dans, un support organique
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61P 19/00 - Médicaments pour le traitement des troubles du squelette
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 27/02 - Agents ophtalmiques
• A61P 35/00 - Agents anticancéreux
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
• C07K 16/42 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des immunoglobulines (anticorps anti-idiotypiques)
• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides

Abrégé

The present invention provides a novel method of utilizing pullulan. For example, the present invention relates to: a pullulan gel which is produced by crosslinking multiple pullulan molecules; a pullulan gel as mentioned above, in which a protein is crosslinked with the pullulan molecules; a dried product of the pullulan gel; a pharmaceutical composition; a protein detection kit; and others. The present invention also relates to: methods respectively for producing these products; and others.

Classes IPC  ?

• C08B 37/00 - Préparation des polysaccharides non prévus dans les groupes Leurs dérivés
• A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
• C07K 1/02 - Procédés généraux de préparation de peptides en solution
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C07K 14/475 - Facteurs de croissanceRégulateurs de croissance
• C07K 14/555 - Interférons [IFN]
• C07K 14/765 - Sérum albumine, p. ex. HSA
• C08B 37/16 - CyclodextrineSes dérivés
• C08J 3/24 - Réticulation, p. ex. vulcanisation, de macromolécules
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

It is intended to provide an IgE peptide vaccine that can be used in the prevention or treatment of allergic diseases in animals other than mice, such as humans or dogs. The present invention provides a peptide consisting of (i) the amino acid sequence represented by SEQ ID NO: 28, or (ii) an amino acid sequence consisting of at least 10 consecutive amino acids in the amino acid sequence represented by SEQ ID NO: 28, wherein the peptide, when administered to an animal, is capable of specifically binding to a CH3 region in an IgE antibody of the animal and thereby blocking the binding of the IgE antibody to an IgE receptor.

Classes IPC  ?

• A61K 38/00 - Préparations médicinales contenant des peptides
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C07K 16/42 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des immunoglobulines (anticorps anti-idiotypiques)
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Produits et services

Chemical preparations for scientific purposes, other than for medical or veterinary use; chemical reagents, other than for medical or veterinary purposes; stem cells other than for medical or veterinary purposes; biological tissue cultures other than for medical or veterinary purposes; cryogenic preparations; chemicals; adhesives for industrial purposes; gums [adhesives], other than for stationery or household purposes; plant growth regulating preparations; reagent paper [not for medical purposes]; biological preparations, other than for medical or veterinary purposes. Pharmaceutical substances; biological preparations for medical purposes; chemical preparations for pharmaceutical purposes; chemical preparations for medical purposes; stem cells for medical purposes; biological tissue cultures for medical purposes; chemical reagents for medical or veterinary purposes; media for bacteriological cultures; stem cells for veterinary purposes; biological tissue cultures for veterinary purposes; reagent paper for medical purposes; pharmaceutical preparations and other preparations for destroying vermin, fungicides, herbicides; menstruation bandages; sanitary panties; sanitary tampons; sanitary napkins; surgical tissues; gauze for dressings; bandages for dressings; sticking plasters for medical use; absorbent cotton; breast-nursing pads; eyepatches for medical purposes; sanitary bandages for dressings; dressings, medical; teeth filling material; dental lacquer; capsules for medical purposes.

Produits et services

Chemical preparations for scientific purposes, other than for medical or veterinary use; chemical reagents, other than for medical or veterinary purposes; stem cells other than for medical or veterinary purposes; biological tissue cultures other than for medical or veterinary purposes; cryogenic preparations; chemicals; adhesives for industrial purposes; gums [adhesives], other than for stationery or household purposes; plant growth regulating preparations; reagent paper [not for medical purposes]; biological preparations, other than for medical or veterinary purposes. Pharmaceutical substances; biological preparations for medical purposes; chemical preparations for pharmaceutical purposes; chemical preparations for medical purposes; stem cells for medical purposes; biological tissue cultures for medical purposes; chemical reagents for medical or veterinary purposes; media for bacteriological cultures; stem cells for veterinary purposes; biological tissue cultures for veterinary purposes; reagent paper for medical purposes; pharmaceutical preparations and other preparations for destroying vermin, fungicides, herbicides; menstruation bandages; sanitary panties; sanitary tampons; sanitary napkins; surgical tissues; gauze for dressings; bandages for dressings; sticking plasters for medical use; absorbent cotton; breast-nursing pads; eyepatches for medical purposes; sanitary bandages for dressings; dressings, medical; teeth filling material; dental lacquer; capsules for medical purposes.

Produits et services

Chemical preparations for scientific purposes, other than for medical or veterinary use; chemical reagents, other than for medical or veterinary purposes; stem cells other than for medical or veterinary purposes; biological tissue cultures other than for medical or veterinary purposes; cryogenic preparations; chemicals; adhesives for industrial purposes; gums [adhesives], other than for stationery or household purposes; plant growth regulating preparations; reagent paper [not for medical purposes]; biological preparations, other than for medical or veterinary purposes. Pharmaceutical substances; biological preparations for medical purposes; chemical preparations for pharmaceutical purposes; chemical preparations for medical purposes; stem cells for medical purposes; biological tissue cultures for medical purposes; chemical reagents for medical or veterinary purposes; media for bacteriological cultures; stem cells for veterinary purposes; biological tissue cultures for veterinary purposes; reagent paper for medical purposes; pharmaceutical preparations and other preparations for destroying vermin, fungicides, herbicides; menstruation bandages; sanitary panties; sanitary tampons; sanitary napkins; surgical tissues; gauze for dressings; bandages for dressings; sticking plasters for medical use; absorbent cotton; breast-nursing pads; eyepatches for medical purposes; sanitary bandages for dressings; dressings, medical; teeth filling material; dental lacquer; capsules for medical purposes.

Abrégé

　The purpose of the present invention is to provide a preparation method for preparing beta-hematin crystals via a heating step, beta-hematin crystals obtained by this preparation method, and a vaccine adjuvant composition containing the beta-hematin crystals. Beta-hematin crystals having an acicular shape, an average particle size of 0.6-1.2 μm, and characteristic main peaks (including any peak having a diffraction angle within ±0.2° of the main peaks) of the diffraction angle 2θ at 7.4°, 12.2°, 21.6°, and 24.1°in x-ray diffraction obtained by powder x-ray diffraction using Cu-Kα radiation.

Classes IPC  ?

• C07D 487/22 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes dans le système condensé, non prévus par les groupes dans lesquels le système condensé contient au moins quatre hétérocycles
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61P 37/04 - Immunostimulants

Produits et services

Chemical preparations for scientific purposes, and for use in industry; investigative chemical reagents for use in cell cryopreservation for non-medical purposes [ Chemical preparations for sanitary purposes; pharmaceutical preparations for use in cell cryopreservation ]

Abrégé

The purpose of the present invention is to provide: a polynucleotide for coding the light-chain variable region and the heavy-chain variable region of an anti-dog IgE antibody; and an anti-dog IgE antibody containing these variable regions. The present invention pertains to: DNA for coding a heavy-chain variable region comprising an amino acid sequence represented by sequence identification number 2 or 6; DNA for coding a light-chain variable region comprising an amino acid sequence represented by sequence identification number 4 or 8; and an anti-dog IgE monoclonal antibody for bonding to dog IgE and containing these variable regions, or a functional fragment thereof which bonds to dog IgE.

Classes IPC  ?

• C07K 16/42 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des immunoglobulines (anticorps anti-idiotypiques)
• C12N 1/15 - ChampignonsLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 1/19 - LevuresLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C12N 15/09 - Technologie d'ADN recombinant
• C12P 21/08 - Anticorps monoclonaux
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

　Provided is an IgE peptide vaccine which can be used in the prevention or treatment of allergic disorders affecting animals other than mice, such as humans and dogs. A peptide comprising (i) an amino acid sequence represented by SEQ. ID No. 28, or (ii) an amino acid sequence containing at least ten continuous amino acids among the amino acid sequence represented by SEQ. ID No. 28, wherein, when the peptide has been administered to an animal, the peptide specifically binds with the CH3 region of IgE antibodies of the animal, preventing the IgE antibodies from binding with IgE receptors.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 11/02 - Agents rhinologiques, p. ex. décongestionnants
• A61P 11/06 - Antiasthmatiques
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A61P 17/04 - Antiprurigineux
• A61P 27/02 - Agents ophtalmiques
• A61P 37/02 - Immunomodulateurs
• A61P 37/04 - Immunostimulants
• A61P 37/08 - Agents antiallergiques
• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux

Produits et services

Chemical preparations; investigative chemical reagents for use in cell cryopreservation. Pharmaceutical preparations; pharmaceutical preparations for use in cell cryopreservation.

Produits et services

Chemical preparations; investigative chemical reagents for use in cell cryopreservation. Pharmaceutical preparations; pharmaceutical preparations for use in cell cryopreservation.

Produits et services

Chemical preparations; investigative chemical reagents for use in cell wash and recovery. Pharmaceutical preparations; pharmaceutical preparations for use in cell wash and recovery.

Produits et services

Chemical preparations for scientific purposes, for use in industry, and for sanitary purposes; investigative chemical reagents for use in cell wash and recovery, for non-medical purposes [ Pharmaceutical preparations for use in cell wash and recovery ]

Produits et services

Chemical preparations for scientific purposes, for use in industry, and for sanitary purposes; investigative chemical reagents for use in cell cryopreservation for non-medical purposes [ Pharmaceutical preparations for use in cell cryopreservation ]

Produits et services

Chemical preparations for scientific purposes, for use in industry, and for sanitary purposes; investigative chemical reagents for use in cell cryopreservation for non-medical purposes [ Pharmaceutical preparations for use in cell cryopreservation ]

Abrégé

A method for removing cauxin in cat urine and a material for removing cauxin are provided. The material for removing cauxin in cat urine comprises a polymer substrate on which surface a trifluoroketone derivative is immobilized via dithiol.

Classes IPC  ?

• C08F 255/02 - Composés macromoléculaires obtenus par polymérisation de monomères sur des polymères d'hydrocarbures tels que définis dans le groupe sur des polymères d'oléfines contenant deux ou trois atomes de carbone
• C08F 257/02 - Composés macromoléculaires obtenus par polymérisation de monomères sur des polymères de monomères aromatiques tels que définis dans le groupe sur des polymères de styrène ou de styrène substitué par des groupes alkyle
• C08F 259/00 - Composés macromoléculaires obtenus par polymérisation de monomères sur des polymères de monomères contenant des halogènes tels que définis dans le groupe
• C08F 263/04 - Composés macromoléculaires obtenus par polymérisation de monomères sur des polymères d'esters d'alcools non saturés avec des acides saturés tels que définis dans le groupe sur des polymères d'esters vinyliques avec des acides monocarboxyliques sur des polymères d'acétate de vinyle
• C08F 283/04 - Composés macromoléculaires obtenus par polymérisation de monomères sur des polymères prévus par la sous-classe sur des polycarbonamides, des polyesteramides ou des polyimides
• C08J 9/36 - Post-traitement
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C12Q 1/44 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase une estérase

Abrégé

Lens culinaris lectin. Detection of the cat urinary protein from which cauxin has been removed is performed with a urine test strip.

Classes IPC  ?

• G01N 33/545 - Résine synthétique
• G01N 33/548 - Hydrates de carbone, p. ex. dextrane

Abrégé

Disclosed are a method for removing the cauxin in cat urine, and a material for removing cauxin. In said material for removing the cauxin in cat urine, a trifluoro ketone derivative is fixed via dithiol to the surface of a polymer substrate.

Classes IPC  ?

• G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• G01N 33/52 - Utilisation de composés ou de compositions pour des recherches colorimétriques, spectrophotométriques ou fluorométriques, p. ex. utilisation de bandes de papier indicateur

Abrégé

Disclosed are: a method for preparing a vaccine adjuvant composition that contains β-hematin; and a vaccine adjuvant composition that is obtained by the preparation method. Specifically disclosed is a vaccine adjuvant composition that contains β-hematin crystals having an average particle diameter of 20-500 nm.

Classes IPC  ?

• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61P 37/08 - Agents antiallergiques

Produits et services

Pharmaceutical and veterinary preparations.

Produits et services

[ Pharmaceutical and ] veterinary preparations, namely, [ preventive preparations for allergy diseases of animals; and ]treatment preparations for allergy diseases for animals

Abrégé

The present invention provides a vaccine adjuvant composition which is used in combination with an allergen vaccine, infection vaccine or tumor vaccine. The present invention specifically provides a vaccine adjuvant composition comprising hemozoin or β-hematin and being used in combination with an allergen vaccine, infection vaccine or tumor vaccine, and a vaccine composition comprising the vaccine adjuvant composition and an allergen vaccine, infection vaccine or tumor vaccine.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61K 47/46 - Ingrédients de constitution indéterminée ou leurs produits de réaction, p. ex. peau, os, lait, fibre de coton, coquille d’œuf, fiel de bœuf ou extraits de plante
• A61K 39/35 - Allergènes

Abrégé

A method for diagnosing a kidney disease in a cat by detecting a cat urinary protein without being affected by cauxin, and a diagnostic agent therefor are provided. A method of detecting a urinary protein derived from renal dysfunction in a cat according to claim 1, wherein cauxin is removed from cat urine by bringing the cat urine into contact with a lectin or an anti-cauxin antibody that specifically binds to cauxin.

Classes IPC  ?

• G01N 33/545 - Résine synthétique
• G01N 33/548 - Hydrates de carbone, p. ex. dextrane

Abrégé

To provide an aqueous solution for cell preservation which is free of a natural animal-derived component such as a basal medium or serum. An aqueous preservation solution showing a high cell survival rate was obtained by removing a natural animal-derived component such as a basal medium or serum and controlling other components and their concentrations.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet

Abrégé

To provide a vaccine adjuvant composition which is to be used in combination with an allergen vaccine, an infection vaccine, a mucosal vaccine or a tumor vaccine. An adjuvant composition which is to be used in combination with an allergen vaccine, an infection vaccine, a mucosal vaccine or a tumor vaccine containing hemozoin or β-hematin; and a vaccine composition which contains the above-described adjuvant composition together with an allergen vaccine, an infection vaccine, a mucosal vaccine or a tumor vaccine.

Classes IPC  ?

• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61K 47/46 - Ingrédients de constitution indéterminée ou leurs produits de réaction, p. ex. peau, os, lait, fibre de coton, coquille d’œuf, fiel de bœuf ou extraits de plante
• A61P 31/04 - Agents antibactériens
• A61P 31/12 - Antiviraux
• A61P 35/00 - Agents anticancéreux

Abrégé

It is intended to provide a method for diagnosing renal disease in a cat by detecting urinary protein of cat without being affected by cauxin and a diagnostic agent therefor. A method of detecting urinary protein derived from renal dysfunction in a cat according to claim 1 in which cauxin is removed from cat urine by bringing the cat urine into contact with lectin or an anti-cauxin antibody that specifically binds to cauxin.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
• G01N 33/52 - Utilisation de composés ou de compositions pour des recherches colorimétriques, spectrophotométriques ou fluorométriques, p. ex. utilisation de bandes de papier indicateur

Abrégé

(b) a protein comprising an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 2 or 35 by deletion, substitution, or addition of one or several amino acids and having mite allergen activity.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/35 - Allergènes
• A61K 39/36 - Allergènes de pollen

Abrégé

Disclosed is a therapeutic agent for a renal disease, a liver disease or a heart disease, a growth stimulator for a tubular cell, an inhibitor of fibrosis of a glomerulus, or a therapeutic agent specific to a damaged organ, which comprises a single-stranded HGF as an active ingredient.

Classes IPC  ?

• A61K 38/22 - Hormones
• A61P 9/04 - Agents inotropes, c.-à-d. stimulants de la contraction cardiaqueMédicaments pour le traitement de l'insuffisance cardiaque
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
• A61P 9/12 - Antihypertenseurs
• A61P 11/06 - Antiasthmatiques
• A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
• A61P 19/06 - Agents antigoutte, p. ex. agents antihyperuricémiants ou uricosuriques
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 35/00 - Agents anticancéreux
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
• A61P 37/02 - Immunomodulateurs
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
• C07K 14/475 - Facteurs de croissanceRégulateurs de croissance

Abrégé

Disclosed is a vaccine for canine distemper virus infection, canine adenovirus type-2 infection, or canine parvovirus infection, which can be orally administered. Specifically disclosed are: an attenuated canine distemper virus strain, which is produced by adapting canine distemper virus strain 95-54 to a culture cell to thereby attenuate the strain; an attenuated canine adenovirus type-2 strain, which is produced by adapting canine adenovirus type-2 strain F1 to a culture cell to thereby attenuate the strain; and an attenuated canine parvovirus strain, which is produced by adapting canine parvovirus strain F3 to a culture cell to thereby attenuate the strain.

Classes IPC  ?

• C12N 7/08 - Inactivation ou atténuationProduction de parties élémentaires de virus par passages successifs de virus
• A61K 39/175 - Virus de la maladie des chiens
• A61K 39/23 - Parvoviridae, p. ex. virus de l'aleucémie féline
• A61K 39/235 - Adenoviridae
• A61P 31/12 - Antiviraux
• C12N 15/09 - Technologie d'ADN recombinant

Abrégé

It is intended to provide a composition for diluting and storing sperm which does not contain a natural animal-derived component such as serum and can maintain a sperm activity at an equal or higher level compared with a conventional liquid for diluting and storing sperm. By removing a natural animal-derived component such as serum and adjusting other components and concentration, the composition for diluting and storing sperm which can maintain a sperm activity at an equal or higher level compared with a conventional liquid for diluting and storing sperm was found.

Classes IPC  ?

• A01N 1/02 - Conservation de parties vivantes
• C12N 1/04 - Conservation des micro-organismes à l'état viable
• C12N 5/06 -

Abrégé

A solidification/packing container for solidifying fluid matter to produce a block-like solidification article and packing the block-like solidification article thus produced. In the solidification/packing container, when a box is formed by folding so that the width end sides (5b, 5b) of first sidewall portions (5, 5) and the width end sides (8b, 8b) of second sidewall portions (8, 8) approach each other, a triangular portion (13) is formed by folding an excessive corner portion (12) to project outward on the diagonal in the radial direction, the triangular portion (13) is folded to overlap on the outer sides of the second sidewall portions (8, 8), retaining walls (11, 11) continuous to the height end sides (8a, 8a) of the second sidewall portions (8, 8) are folded to overlap the triangular portion (13), and the latches (10, 10) of the retaining walls (11, 11) are inserted to the inner side of the hypotenuse (13a) of the triangular portion (13) and secured in place. Consequently, a solidification/packing container (2) for both solidifying fluid matter and packing a block-like solidification article is obtained.

Classes IPC  ?

• B65D 77/02 - Objets enveloppés enfermés dans des réceptacles rigides ou semi-rigides
• A23K 1/00 - Produits alimentaires pour animaux
• B65D 5/24 - Réceptacles de section transversale polygonale rigides ou semi-rigides, p. ex. boîtes, cartons ou plateaux, formés en pliant ou montant un ou plusieurs flans de papier en repliant les parties reliées à un panneau central sur chaque côté pour former le corps du réceptacle, p. ex. en forme de plateau avec des côtés adjacents reliés par des plis à soufflet

Abrégé

Efficient production of a feed pellet containing water and organic matter and being capable of stably containing vitamins. Solidified pellet containing organic matter and water is obtained through preparing of a first composition containing calcium phosphate (I) and a second composition containing calcium phosphate (II) from a first agent consisting of 14 to 22 wt.% of calcium phosphate (I) (molar ratio of Ca:P = 1:1.5 to 2.5), a second agent consisting of 4 to 12 wt.% of calcium phosphate (II) (molar ratio of Ca:P = 1:0.5 to 1.0), 5 to 25 wt.% of organic matter to be mixed in at least either the first agent or the second agent and 2 to 10 wt.% of water to be mixed in at least either the first agent or the second agent, kneading of the first composition and the second composition together and pelletizing of the resultant kneaded matter.

Classes IPC  ?

• A23K 1/20 - Gâteaux ou briquettes
• A23K 1/175 - avec des substances inorganiques; Blocs de sel
• A23N 17/00 - Appareils spécialement adaptés pour la préparation de la nourriture des animaux

Produits et services

Chemical preservatives; preservatives for pharmaceutical preparations. Preservative preparations of semen used for artificial insemination for animals. Artificial insemination.

Produits et services

Pharmaceuticals for veterinary purposes. Medical veterinary apparatus, medical veterinary instruments. Animal food, animal food additive for use as a nutritional supplement.

Produits et services

Medicated soaps for animals, pharmaceuticals for veterinary purposes. Medical apparatus, medical instruments. Animal food, animal food additive for use as a nutritional supplement.